Price
$1.51
Increased by 0.00%
Dollar volume (20D)
96.30 K
ADR%
1.29
Earnings report date
Mar 26, 2025
Shares float
5.14 M
Shares short
222.10 K [4.32%]
Shares outstanding
6.90 M
Market cap
10.43 M
Beta
1.58
Price/earnings
N/A
20D range
1.44 1.52
50D range
0.31 1.52
200D range
0.20 2.61

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States.

It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch.

The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

As of August 26, 2024, Agile Therapeutics, Inc. operates as a subsidiary of Exeltis USA, Inc.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 15, 24 0.28
Increased by +104.69%
-0.51
Increased by +154.35%
Mar 28, 24 -1.51
Increased by +69.80%
-0.92
Decreased by -64.13%
Nov 9, 23 -0.27
Increased by +49.06%
-1.84
Increased by +85.33%
Aug 9, 23 -2.15
Increased by +20.66%
-7.00
Increased by +69.29%
May 11, 23 -5.91
Decreased by -56.35%
-7.50
Increased by +21.20%
Mar 22, 23 -5.00
Increased by +37.50%
-11.50
Increased by +56.52%
Nov 7, 22 -0.53
Increased by +92.64%
-0.44
Decreased by -20.45%
Aug 11, 22 -2.71
Increased by +66.13%
-3.70
Increased by +26.76%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 24 5.58 M
Increased by +1.33%
-11.87 M
Decreased by -211.68%
Decreased by -212.91%
Decreased by -207.60%
Mar 31, 24 5.72 M
Increased by +49.91%
1.28 M
Increased by +135.57%
Increased by +22.46%
Increased by +123.73%
Dec 31, 23 3.61 M
Decreased by -9.56%
-4.47 M
Increased by +66.34%
Decreased by -123.69%
Increased by +62.78%
Sep 30, 23 6.66 M
Increased by +121.92%
-799.00 K
Increased by +96.38%
Decreased by -11.99%
Increased by +98.37%
Jun 30, 23 5.50 M
Increased by +158.84%
-3.81 M
Increased by +68.83%
Decreased by -69.22%
Increased by +87.96%
Mar 31, 23 3.81 M
Increased by +116.52%
-3.61 M
Increased by +69.33%
Decreased by -94.68%
Increased by +85.83%
Dec 31, 22 4.00 M
Increased by +163.94%
-13.28 M
Increased by +43.15%
Decreased by -332.31%
Increased by +78.46%
Sep 30, 22 3.00 M
Increased by +133.26%
-22.05 M
Decreased by -31.46%
Decreased by -734.48%
Increased by +43.64%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY